store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
C24:1 3'-sulfo Galactosylceramide (d18:1/24:1(15Z))是成熟髓鞘中主要的硫酸盐类化合物。C24:1 3'-sulfo Galactosylceramide (d18:1/24:1(15Z)) 在大鼠小脑中发现活跃的髓发生鞘化反应时积累率高于C24 3'-sulfo 半乳糖甘油酰胺。C24:1 3'-sulfo Galactosylceramide (d18:1/24:1(15Z))与C 型凝集素和免疫球蛋白样受体相互作用使对LMIR5的亲和力高。C24:1 3'-sulfo Galactosylceramide (d18:1/24:1(15Z))诱导嗜碱细胞产生MCP-1,可通过增加LMIR5激活NFAT,但不能诱导肥大细胞 。C24:1 3'-sulfo Galactosylceramide (d18:1/24:1(15Z))在体外与CD1d 结合,并增加游离小鼠脾细胞的增殖。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 11,680 | 待询 |
产品描述 | C24:1 3'-sulfo Galactosylceramide (d18:1/24:1(15Z)) is the predominant sulfate analog in the mature myelin sheath. C24:1 3'-sulfo Galactosylceramide (d18:1/24:1(15Z)) interacted with C-type lectin and immunoglobulin-like receptors to give the highest affinity for LMIR5. Galactosylceramide (d18:1/24:1(15Z)) induces MCP-1 production by basophils, which activates NFAT by increasing LMIR5, but not mast cells .C24:1 3'-sulfo Galactosylceramide (d18:1/24:1(15Z)) binds in vitro to CD1d binding and increased the proliferation of free mouse splenocytes. |
体外活性 | The relationship between structure and activity (SAR) of newly synthesized sulfatide isoforms C24:1 was evaluated. The basal IDO1 expression was significantly increased by C24:1 sulfatide (+87 ± 7% and +50 ± 5% at 1μΜ, respectively) over negative controls ; These effects functionally correlated with changes in IDO1 activity: l-kynurenine contents in the culture media were significantly increased by C24:1 sulfatide (+61 ± 8% and +48 ± 4% at 1μM, respectively) over negative controls.[2] |
别名 | C24:1 3'-sulfo Galactosylceramide (d18:1/24:1(15Z)) |
分子量 | 890.3 |
分子式 | C48H91NO11S |
CAS No. | 151057-28-2 |
store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Chloroform:Methanol (5:1): Soluble
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
C24:1 3'-sulfo Galactosylceramide (d18:1/24:1(15Z)) 151057-28-2 Others C24:1 3' sulfo Galactosylceramide (d18:1/24:1(15Z)) C24:1 3'sulfo Galactosylceramide (d18:1/24:1(15Z)) C-24:1 3'-sulfo Galactosylceramide (d18:1/24:1(15Z)) C24:1 3'-sulfo Galactosylceramide (d18:1/24:1) Inhibitor inhibitor inhibit